Four-factor Prothrombin Complex Concentrate for the Management of Patients Receiving Direct Oral Activated Factor X Inhibitors-Reference-Cited by-同舟云学术

Four-factor Prothrombin Complex Concentrate for the Management of Patients Receiving Direct Oral Activated Factor X Inhibitors

Published:2019-11-01 Issue:5 Volume:131 Page:1153-1165
ISSN:0003-3022
Container-title:Anesthesiology
language:en
Short-container-title:

Author:

Grottke Oliver¹,Schulman Sam¹

Affiliation:

1. From the Department of Anesthesiology, Rheinisch-Westfälische Technische Hochschule Aachen University Hospital, Germany (O.G.); Thrombosis and Atherosclerosis Research Institute and Department of Medicine, McMaster University, Hamilton, Canada (S.S.); and Department of Obstetrics and Gynecology, The First I.M. Sechenov Moscow State Medical University, Russia (S.S.).

Abstract

Factor Xa inhibitors prevent thrombosis but are associated with severe or life-threatening bleeding. Here, the authors present data on four-factor prothrombin complex concentrates in management of anticoagulation-associated bleeding and restoring hemostasis, including recent results from the UPRATE study.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Anesthesiology and Pain Medicine

Link

http://pubs.asahq.org/anesthesiology/article-pdf/131/5/1153/460666/20191100_0-00033.pdf

Reference83 articles.

1. A review of warfarin dosing and monitoring.;Proc (Bayl Univ Med Cent),2001

2. New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events.;Ther Clin Risk Manag,2015

3. The significance of drug-drug and drug-food interactions of oral anticoagulation.;Arrhythm Electrophysiol Rev,2018

4. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials.;Lancet,2014

5. Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1.;Eur Heart J Cardiovasc Pharmacother,2019

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A review of the perioperative management of direct oral anticoagulants for pediatric anesthesiologists;Pediatric Anesthesia;2024-09-08

2. Anticoagulation reversal (vitamin K, prothrombin complex concentrates, idarucizumab, andexanet‐α, protamine);British Journal of Clinical Pharmacology;2024-06-26

3. Clinical guideline on reversal of direct oral anticoagulants in patients with life threatening bleeding;European Journal of Anaesthesiology;2024-04-04

4. Antidote vs. unspecific hemostatic agents for the management of direct oral anticoagulant-related bleeding in trauma;Current Opinion in Anaesthesiology;2024-01-19

5. Clinical Relevance of Preclinical and Clinical Studies of Four-Factor Prothrombin Complex Concentrate for Treatment of Bleeding Related to Direct Oral Anticoagulants;Annals of Emergency Medicine;2023-09